| XMD17 109 |
XMD17 109 |
1435488-37-1 |
| CH5132799 |
CH5132799 |
1007207-67-1 |
| PD04217903 |
2-[4-[1-(喹啉-6-甲基)-1H-[1,2,3]三唑并[4,5-B]吡嗪-6-基]-1H-吡唑-1-基]乙醇 |
956905-27-4 |
| LY2409881 trihydrochloride |
IKK2抑制剂（LY2409881） |
946518-60-1 |
| SCH772984 |
(R)-1-(2--2-氧(4-(4-(嘧啶-2-基)苯基)对二氮己环-1-基)乙基)-N-(3-(吡啶-4-基)-1H--5INDAZOL-基)吡咯烷-3-甲酰胺 |
942183-80-4 |
| Ibrutinib |
依鲁替尼 |
936563-96-1 |
| 5-Chloro-N2-[(1S)-1-(5-fluoro-2-pyrimidinyl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)-2,4-pyrimidinediamine |
5-氯-N2-[(1S)-1-(5-氟-2-嘧啶基)乙基]-N4-(5-甲基-1H-吡唑-3-基)-2,4-嘧啶二胺 |
935666-88-9 |
| indoleaMine-2,3-dioxygenase inhibitor INCB024360 |
4-氨基-N-(3-氯-4-氟苯基)-N'-羟基-1,2,5-恶二唑-3-甲脒 |
914471-09-3 |
| PIK-294 |
PIK-294 |
900185-02-6 |
| 6-Amino-8-[(6-iodo-1,3-benzodioxol-5-yl)thio]-N-(1-methylethyl)-9H-purine-9-propanamine |
6-氨基-8-[(6-碘-1,3-苯并二茂-5-基)硫基]-N-异丙基-9H-嘌呤-9-丙胺 |
873436-91-0 |
| MLN-120B |
N-(6-氯-7-甲氧基-9H-吡啶并[3,4-B]吲哚-8-基)-2-甲基-3-吡啶甲酰胺 |
783348-36-7 |
| Linifanib (ABT-869) |
利尼伐尼 |
796967-16-3 |
| Olaparib |
奥拉帕尼 |
763113-22-0 |
| VX 702 |
6-[(氨基羰基)(2,6-二氟苯基)氨基]-2-(2,4-二氟苯基)-3-吡啶甲酰胺 |
745833-23-2 |
| LY2109761 |
LY2109761 |
700874-71-1 |
| REVERSINE |
REVERSINE |
656820-32-5 |
| Tozasertib |
陶扎色替 |
639089-54-6 |
| AZD 1080 |
AZD1080 |
612487-72-6 |
| Selumetinib |
司美替尼 |
606143-52-6 |
| 2-(4-broMo-2-chlorophenoxy)-N-(4-(N-(4,6-diMethylpyriMidin-2-yl)sulfaMoyl)phenylcarbaMothioyl)acetaMide |
ZCL278 |
587841-73-4 |
